Cardiovascular drugs and therapy · 2026
Guideline-directed Low-density Lipoprotein Cholesterol Management After Acute Coronary Syndrome in Patients With Mental Illness: a Population-based Study.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Avidan Yuval, Kobo Ofer, Weizman Baruch, Jonas Matan, Hadar Dana, Zafrir Barak, Kassem Sameer
Аннотация
BACKGROUND: Despite increased cardiovascular morbidity among patients with mental disorders, real-world data on lipid-lowering therapy (LLT) use and low-density lipoprotein cholesterol (LDL-C) target attainment after acute coronary syndrome (ACS) remain limited. We evaluated disparities in LLT utilization and LDL-C target attainment among patients with and without mental disorders following ACS in a real-world setting.
METHODS: Data of consecutive ACS hospitalizations in a large healthcare system (2013-2023) were analyzed. Patients were stratified by mental illness and compared with controls. LDL-C target attainment and LLT use were assessed at baseline and during early (1-4 months) and late (6-12 months) post-discharge periods. Multivariable logistic regression evaluated independent associations.
RESULTS: Among 9,192 patients surviving ≥ 1 year after ACS, 32.1% had mental illness. These patients were older, more often female, and had higher atherosclerotic burden (p < 0.001). LDL-C target attainment was lower in patients with mental illness both early (49% vs. 54%) and late (44% vs. 49%) after discharge, with fewer achieving ≥ 50% LDL-C reduction (p < 0.001). High-intensity statin and early ezetimibe use were less frequent (p = 0.005), and non-adherence was higher (9.7% vs. 6.3%, p = 0.001). In adjusted analyses, mental illness was not independently associated with LDL-C target attainment but was linked to lower use of moderate- and high-intensity statins (OR 0.87 and 0.83) and higher likelihood of no LLT use (OR 1.48; p < 0.01).
CONCLUSIONS: Mental disorders were associated with lower LLT intensity and greater treatment gaps after ACS, without independent differences in LDL-C attainment. LDL-C control and combination LLT use remained suboptimal, highlighting persistent gaps in secondary prevention.
METHODS: Data of consecutive ACS hospitalizations in a large healthcare system (2013-2023) were analyzed. Patients were stratified by mental illness and compared with controls. LDL-C target attainment and LLT use were assessed at baseline and during early (1-4 months) and late (6-12 months) post-discharge periods. Multivariable logistic regression evaluated independent associations.
RESULTS: Among 9,192 patients surviving ≥ 1 year after ACS, 32.1% had mental illness. These patients were older, more often female, and had higher atherosclerotic burden (p < 0.001). LDL-C target attainment was lower in patients with mental illness both early (49% vs. 54%) and late (44% vs. 49%) after discharge, with fewer achieving ≥ 50% LDL-C reduction (p < 0.001). High-intensity statin and early ezetimibe use were less frequent (p = 0.005), and non-adherence was higher (9.7% vs. 6.3%, p = 0.001). In adjusted analyses, mental illness was not independently associated with LDL-C target attainment but was linked to lower use of moderate- and high-intensity statins (OR 0.87 and 0.83) and higher likelihood of no LLT use (OR 1.48; p < 0.01).
CONCLUSIONS: Mental disorders were associated with lower LLT intensity and greater treatment gaps after ACS, without independent differences in LDL-C attainment. LDL-C control and combination LLT use remained suboptimal, highlighting persistent gaps in secondary prevention.